Psychosis in Parkinson's Disease: A Lesson from Genetics

Genes (Basel). 2022 Jun 20;13(6):1099. doi: 10.3390/genes13061099.

Abstract

Psychosis in Parkinson's disease (PDP) represents a common and debilitating condition that complicates Parkinson's disease (PD), mainly in the later stages. The spectrum of psychotic symptoms are heterogeneous, ranging from minor phenomena of mild illusions, passage hallucinations and sense of presence to severe psychosis consisting of visual hallucinations (and rarely, auditory and tactile or gustatory) and paranoid delusions. PDP is associated with increased caregiver stress, poorer quality of life for patients and carers, reduced survival and risk of institutionalization with a significant burden on the healthcare system. Although several risk factors for PDP development have been identified, such as aging, sleep disturbances, long history of PD, cognitive impairment, depression and visual disorders, the pathophysiology of psychosis in PD is complex and still insufficiently clarified. Additionally, several drugs used to treat PD can aggravate or even precipitate PDP. Herein, we reviewed and critically analyzed recent studies exploring the genetic architecture of psychosis in PD in order to further understand the pathophysiology of PDP, the risk factors as well as the most suitable therapeutic strategies.

Keywords: Parkinson’s disease; genetics; psychosis.

Publication types

  • Review

MeSH terms

  • Hallucinations / complications
  • Hallucinations / diagnosis
  • Hallucinations / genetics
  • Humans
  • Parkinson Disease* / genetics
  • Psychotic Disorders* / diagnosis
  • Psychotic Disorders* / genetics
  • Quality of Life
  • Risk Factors

Grants and funding

This research received no external funding.